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Toxic epidermal necrolysis (TEN) is a rare severe disease of the skin and mucous membranes. It is considered a potentially fatal medical emergency [1] with a mortality 
rate of 25-30% [2]. TEN was first described in 1956 by Lyell [3]. 
Drugs are the most common cause of TEN and antiepileptics, 
sulfonamide antibiotics, penicillins, allopurinol, and oxicam 
nonsteroidal anti-inflammatory drugs (NSAID’s) are the drugs 
commonly implicated in the development of TEN [4]. The 
pathogenesis of TEN is not fully understood but is believed to 
be immune-mediated as recurrence of TEN on re-challenging 
an individual with the same drug has been reported [5,6]. The 
clinical hallmark of TEN is a marked skin detachment caused 
by extensive keratinocyte apoptosis associated with mucosal 
involvement [7].
The incidence in adults is estimated to be between 0.4 and 
1.2 cases/1 million people per year [8-12]. The disease is rarer 
in children compared to the adults [13,14]. There are very few 
studies on TEN in children. Most of the publications only present 
low number of pediatric patients ranging from 3 to 20 [15-20]. 
Mortality rate as high as 60% has been reported in children [17]. 
Studies including at least 10 children with TEN have reported 
a mortality rate range of 7-36%. Regional differences in the 
drug prescription and the genetic background of patients 
(human leukocyte antigen [HLA], metabolizing enzymes), 
can have an impact on the incidence of TEN [21,22]. Optimal 
treatment of TEN is controversial. Treatment with intravenous 
immunoglobulin (IVIG), steroids, cyclophosphamide, 
cyclosporine, and plasmapheresis has been described with 
varying effect. To decrease the rate of infection and protect the 
unhealed areas of skin with topical antibiotics, porcine xenograft, 
human skin allograft, etc., has been used [16,18,23,24]. Infections 
are the most common cause of death in TEN accounting for 50% 
of all deaths in TEN [25]. Infection rate as high as 90% has been 
reported in children [20].
Being a rare life-threatening disease, there is limited data 
regarding clinical and laboratory profile, complications, risk 
factors for septicemia, and outcome in children with TEN. 
This study was undertaken to study the clinical and laboratory 
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profile, risk factors for the development of blood culture positive 
septicemia and treatment outcome of children with TEN being 
treated in a resource-limited setting.
METHODS
This prospective observational study was conducted at pediatric 
intensive care unit (PICU) in Government Medical College, 
Thiruvananthapuram. All children admitted to PICU with TEN 
from January 2012 to January 2017 were included in the study. 
Patients were defined as experiencing TEN if they had large 
confluent blisters with positive Nikolsky’s sign and involvement 
of more than 30% of total body surface area (TBSA). All children 
were also seen by a dermatologist for confirmation of the 
diagnosis. Children with other exfoliative skin diseases and those 
with skin involvement <30% of TBSA were excluded from the 
study.
Complete blood counts, C-reactive protein (CRP), blood 
culture, serum urea, serum creatinine, aspartate aminotransferase 
(AST), alanine aminotransferase (ALT), serum albumin, and 
serum electrolytes were sent in all cases. All children were 
managed in PICU with reverse isolation. Children were given 
daily skin care by cleaning of wounds and irrigation of intact skin 
with normal saline and whole body covered with autoclaved liquid 
paraffin soaked gauze (Fig. 1). Blisters were not punctured, and 
active debridement was not done. Antibiotic ointments were not 
applied routinely. They were used only for visibly infected areas 
after taking swabs for culture. All clothes and bed sheets of the 
patient for daily use were autoclaved. Caretakers were educated 
regarding the importance of asepsis. All cases were seen by an 
ophthalmologist and reviewed every alternate day. Caretakers 
were taught to provide eye care with 2 hourly lubricant drops and 
ointment and daily swiping of fornices to prevent synechiae. They 
were treated with the standard unit protocol of IVIG, injection 
betamethasone, and other supportive measures.
Data were collected using prestructured pro forma. Risk 
factors studied for the development of culture positive septicemia 
included the area of skin involvement more than 80%, mechanical 
ventilation, multi-organ dysfunction, and hyperglycemia 
(>180 mg/dl). All these risk factors were treated as dichotomous 
variables, and Chi-square test was used for analysis. We also 
looked into the total duration of hospital stay and outcome at 
discharge and follow-up after 2 months. For continuous variables, 
mean and standard deviation was calculated, and the categorical 
variables were analyzed by Chi-square test.
RESULTS
Of 9967 PICU admissions, 13 patients were admitted with a 
clinical diagnosis of TEN including 7 males and 6 females with 
a mean age of 7.9±3.2 years. There were no cases of TEN below 
4 years of age. Mean area of skin involvement was 69±19.9% of 
TBSA, and 7 cases (54%) had more than 80% skin involvement 
(Table 1). There was a history of drug ingestion before the onset 
of symptoms in 12 (92%) cases. In one case, there was no history 
of any drug ingestion. Anti-epileptic drugs (AEDs) were the 
causative agent in 5 cases (38%), while in 8 cases (62%), there was 
a history of ingestion of antipyretics (mefenamic acid in 5 cases 
and paracetamol in 3 cases). In 2 cases, there was co-ingestion 
of amoxicillin. All cases of TEN due to AEDs occurred after the 
1st week of starting the AED (4 cases in 2nd week and 1 case in 
4th week). In only 2 cases, there was a prior history of drug allergy 
(1 to amoxicillin and 1 to paracetamol).
A total of 11 cases (85%) had a fever at onset of skin rash that 
lasted for 2-7 days. 4 children (31%) had clinical and radiological 
evidence of the involvement of respiratory tract, out of which 
3 had acute respiratory distress syndrome (ARDS). 7 (54%) 
children had involvement of gastrointestinal tract manifested as 
vomiting, abdominal distension, diarrhea, or feed intolerance 
(Fig. 2). All cases had ophthalmic involvement. Evidence of renal 
injury was seen in 6 cases (46%), out of which 5 had acute kidney 
injury (AKI) Stage II and I had AKI Stage III requiring renal 
replacement therapy.
Total blood count was normal (4000-11000 cells/mm3) in 
9 cases (69%), while 2 cases (15%) had leukocytosis and 2 had 
leukopenia. In children with >80% skin involvement, 4 had 
normal counts, 2 had leukocytosis, and 1 leukopenia, while in 
children with skin involvement <80%, 1 had leukopenia and 5 had 
normal counts. There was no statistically significant association 
between total leukocyte count and severity of skin or systemic 
involvement. Respiratory involvement was seen in 4 cases at 
admission, out of which 2 had leukopenia, and 2 had normal 
counts. Three of the four cases with pulmonary involvement had 
evidence of severe ARDS and needed mechanical ventilation. 
Thrombocytopenia <10000 cells/mm3 was seen in only 1 case. 
CRP was elevated in 9 cases at admission; however, in 2 cases, 
CRP was not estimated at admission. Blood culture was sent at 
admission in all cases and was found to be sterile in all cases. 
3 cases subsequently developed blood culture positive septicemia. 
Organisms isolated were hemolytic Streptococci, Acinetobacter 
species, and Pseudomonas in one case each. All three cases had 
more than 80% skin involvement, and two of them also had 
multiorgan dysfunction and ARDS.
Figure 1: (a) Extensive skin involvement in a child with toxic 
epidermal necrolysis, (b) skin being covered with paraffin 
impregnated gauze after irrigation with normal saline
ba
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Serum sodium level was abnormal in 11 cases (85%). 
Hyponatremia was the most common electrolyte abnormality 
observed it was seen in 8 cases (62%), while hypernatremia was 
seen in 3 (23%) cases. Abnormalities of serum sodium level was 
seen in all children with skin involvement >80% (p<0.1), 5 cases 
(71%) had hyponatremia and 2 (29%) had hypernatremia. In 
children with skin involvement <80%, 3 had hyponatremia (50%), 
and 1 had hypernatremia (33%). Hyperglycemia >180 mg/dl 
requiring insulin infusion occurred in only 3 cases (23%), out 
of which 2 had multi-organ dysfunction and Gram-negative 
septicemia, while in one case, skin swab from penile skin lesion 
grew Acinetobacter species while his blood culture was sterile. 
Hyperglycemia was found to be a risk factor for the development 
of culture positive septicemia (p<0.01). Hypoalbuminemia was 
seen in 10 cases (77%). Serum AST >40 IU/L was seen win 
6 cases while AST >100 IU/L at admission was seen in only 
2 cases, and both had skin involvement >80% and ARDS. In both 
these cases, AST subsequently increased to 795 and 2030 IU/L, 
respectively. In both these cases, ALT was also >50 IU/L. In all 
other children, ALT was normal at admission. High AST values 
above 100 IU/L was associated with severe systemic involvement 
in TEN (p<0.001).
Progression of skin lesions stopped within 5 days in 11 (85%) 
cases. In one case, new necrotizing lesions continued to appear 
till the child succumbed to multiorgan dysfunction on day 14 
(Fig. 3). 6 children received 2 g/kg IVIG, while 3 received 3 g/kg 
and 4 received 1 g/kg IVIG due to cost constraints. There was no 
statistically significant difference in the duration of progression 
of skin lesions between those who received >2 g/kg IVIG and 
those who received <2 g/kg of IVIG. All children received 
parenteral steroids also as injection betamethasone in a dose of 
0.1-0.2 mg/kg/dose 8 hourly.
The median duration of hospital stay was 18 days (range 
8-75 days). There was only one death with mortality rate of 7.6%, 
and this child succumbed on day 14 after admission. This child 
had multi-organ dysfunction, oliguric renal failure requiring 
dialysis for renal support, liver failure, and catecholamine-
refractory shock, ARDS requiring ventilator support on the 
day of admission, Pseudomonas septicemia and disseminated 
intravascular coagulation. The inciting drug was mefenamic 
acid. The children were followed up for a variable period from 
2 months to 1 year. One child was lost to follow-up. All other 
children had skin dyspigmentation at follow-up and none had 
Figure 2: Intravenous immunoglobulin dose and duration of 
progression of skin lesions
Figure 3: Complications in children with toxic epidermal necrolysis
Table 1: Clinical and laboratory profile of children with TEN
Age
years/sex
TBSA 
involving 
%
Inciting drug Duration of 
progression 
(days)
Duration 
of hospital 
stay (days)
TLC 
(cells/mm3)
IVIG 
(g/kg)
AKI 
stage
Serum sodium 
mEq/L 
5/female 85 Mefanamic acid 4 20 14000 2 II 127
5/female 78 Carbamazepine 4 13 13000 2 0 124
12/female 86 Homeopathic medicine 3 10 5600 1 0 132
5/male 88 Mefanamic acid 4 75 5200 1 II 150
5/male 92 Lamotrigine 6 24 5900 3 0 130
11/male 54 Mefanamic acid/phenytoin 5 12 5700 2 0 128
4/male 45 No drugs 5 10 7000 3 0 132
6/male 56 Mefanamic acid 5 11 3300 1 II 150
9/male 88 Mefanamic acid/amoxicillin 14 14 3500 1 III 154
6/female 46 Paracetamol/amoxicillin 4 10 4400 3 0 137
12/female 47 Paracetamol 3 13  7800 1 0 121
11/female 86 Carbamazepine 5 8 5100 2 II 129
12/male 46 Paracetamol 3 10 10,000 2 II 133
IVIG: Intravenous immunoglobulin, TEN: Toxic epidermal necrolysis, TBSA: Total body surface area, TLC: Total leucocyte count, AKI: Acute kidney Injury (0: No injury, Stage 
I: Increase in serum creatinine by 1.5-1.9 times baseline, Stage II: Increase in serum creatinine by 2-2.9 times, Stage III: Serum creatinine increase>3 times baseline)
Vol 4 | Issue 2 | Apr - Jun 2017 Indian J Child Health 148
Sugunan et al. Toxic epidermal necrolysis 
scarring. 6 (46%) of children had ophthalmic complaints at 
follow-up such as itching, conjunctival xerosis, nasolacrimal duct 
obstruction, and chronic conjunctivitis.
DISCUSSION
TEN is a rare mucocutaneous disease accounting for 0.12% of 
total PICU admission in our study, and a total of 13 patients were 
during the 5-year study period. The mean area of skin involvement 
was 69.3±19.9%, and drugs were found to be the most common 
cause of TEN, accounting for 12 (92%) cases. Other studies have 
also implicated drugs as the causative agent in TEN in 77-100% 
cases [8-11,24]. NSAID’s were the most common accounting 
for 8 (62%) cases, while antibiotics were implicated in only 
2 cases (15%). In a survey of TEN in children by Levi et al. [26], 
a possibly increased susceptibility to acetaminophen in children 
compared to adults was observed. In a study by Spies et al. [24], 
antibiotics were implicated in 73% of the cases. A study from 
West Germany [11] has also reported antibiotics as the most 
common causative drug. In our study, antibiotics were implicated 
in only 2 cases (15%), which is in accordance with studies from 
India by Mangla et al. [27] and Das et al. [28] where antibiotics 
were implicated in only 20% of the cases.
TEN due to AEDs occurred within 4 weeks of introduction 
of the drug as has been described before by Roujeau et al. [29]. 
In all cases where NSAID’s or antibiotics were implicated, the 
symptoms started within 48 h of ingestion of the drug while in 
cases of AEDs, it was reported after 1 week of starting the drug. 
In the study by Spies et al. [24], the mean duration of medication 
until the first symptoms of TEN occurred was 11±2 days. 
Regional differences in drug prescription and genetic background 
of patients (HLA, metabolizing enzymes, etc.) may be responsible 
for the difference in the clinical presentation. A unique and strong 
association between HLA, drug hypersensitivity, and ethnic 
background has been discovered by Chung et al. [30].
Fever at the onset of symptoms was present in 10 cases (83%) 
as has been described in other studies. The absence of blood 
stream infection (documented by a negative blood culture in 
92% cases at admission) despite having a fever in 11 (85%) and 
positive CRP in 9 (69%) cases at admission highlight the fact that 
sepsis develops during the disease and not at the onset. Hence, 
prophylactic antibiotics at admission in these children seem to be 
of doubtful value. Surveillance cultures from skin and blood, and 
starting antibiotics on the reappearance of fever or other systemic 
signs of infection appears to be a more rational approach. 
Staphylococcal aureus has been described as a common cause of 
early onset septicemia in patients with TEN [25,31], but in our 
study, there were no cases of Staphylococcal septicemia. There 
were two cases of Gram-negative septicemia (1 Acinetobacter 
species and 1 Pseudomonas) which has been reported in other 
studies also [30,32]. Infections and sepsis are the main causes 
of death in TEN patients [33,34]. Skin involvement >80% 
(p<0.1), multi-organ dysfunction (p<0.01), and need for invasive 
ventilation (p<0.01) were found to be associated with increased 
risk of developing culture positive sepsis in our study. Leukopenia 
has been described as a bad prognostic indicator [34], but in our 
study, total blood counts did not show any relation with extent 
of skin involvement, duration of hospital stay or development of 
multiorgan dysfunction.
Evidence of AKI was seen in 6 cases (46%) and a child with 
AKI Stage III developed anuric renal failure with multi-organ 
dysfunction, and renal support was provided with peritoneal 
dialysis. High serum urea is considered a bad prognostic 
indicator [34] but the staging of renal injury has not been done 
in other studies. The high incidence of renal injury and favorable 
outcome with conservative treatment points to the need of 
meticulous fluid therapy in these children and need for avoidance 
of nephrotoxic drugs in all children with TEN. Pulmonary 
involvement was seen in 4 cases (31%), of which three needed 
invasive ventilation within 24 h of admission for ARDS. 
Endotracheal aspirate sent soon after intubation was found to be 
sterile in all the three ventilated children. Early onset of respiratory 
symptoms and sterile endotracheal aspirate points to the fact 
that respiratory symptoms in TEN is often due to involvement 
of respiratory mucosa by the disease  and not due to secondary 
infection. Gastrointestinal tract involvement in the form of 
vomiting, abdominal distension, diarrhea, or feed intolerance was 
seen in 6 (46%) cases. Similar pulmonary and gastrointestinal 
involvement has been reported in other studies [24].
Serum sodium level was abnormal in 11 cases (85%) at 
admission with hyponatremia in 8 and hypernatremia in 3 cases. 
In the study by Bastuji-Garin et al. [34], abnormal sodium level 
was seen in only 6% of the cases; however, this study mainly 
included adults with a mean age of 42.3±19.8 years. The high 
incidence of sodium imbalance in our study may be because 
children with their larger body surface area compared to adults 
are more susceptible for water and electrolyte loss through 
their skin. Hyperglycemia at admission has been found to 
be a bad prognostic indicator [34]. In this study, no case had 
hyperglycemia at admission. Three children subsequently 
developed hyperglycemia with a blood glucose level >180 mg/dl 
and required insulin infusion. All the three cases had evidence 
of infection at the time of hyperglycemia. Hyperglycemia was 
found to be a marker of secondary bacterial infection (p<0.01). 
Hypoalbuminemia was found in 77% of children with TEN. 
AST was elevated in 6 (46%) children. Bastuji-Garin et al. also 
reported AST level >40 IU/L in 59% of patients with TEN. In our 
study, AST >100 IU/L was observed in only 2 cases and both of 
these cases had skin involvement of >80% TBSA, multi-organ 
dysfunction, and ARDS. 1 child had a prolonged hospital stay 
of 75 days and needed invasive ventilation for 56 days while 
the other child also needed ventilatory support on the day of 
admission and succumbed to multiorgan dysfunction on day 14 
after admission. High AST levels >100 IU/L at admission was 
found to be a marker of severe systemic involvement in TEN 
(p<0.001).
In 85% of cases, the skin lesions stopped progressing by 
day 5 of onset of symptoms. We did not find a significant 
difference in duration of progression of skin lesions in children 
who received either <2 or >2 g/kg of IVIG. Many studies have 
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investigated the role of IVIG in TEN, but the results have been 
conflicting [35-37]. Studies showing both dose-dependent survival 
benefit with IVIG and studies showing no mortality benefit 
compared with supportive therapy alone or when compared with 
the mortality predicted by score for TEN have been reported in 
literature [36-38]. Mangla et al. [27], in 10 children with TEN, 
used low-dose IVIG (0.05-0.1 g/kg/day for 5 consecutive days) 
and reported a beneficial effect with no mortality. Tristani-Firouzi 
et al. [39] in a retrospective study in pediatric population using 
IVIG (0.5-0.75 g/kg/day ×4 days) in 8 children also found it to be 
efficacious. A lower dose of IVIG (<2 g/kg) was found to be a safe 
and efficacious treatment for TEN in our study also. Progression 
of skin lesions beyond day 7 of onset of symptoms was associated 
with poor outcome (p<0.05).
There was only one death with mortality rate of 7.6% which 
is less than the previously reported mortality rate of 25-30% [1]. 
Mortality rate, as high as 60%, has been reported in children with 
severe TEN [17]. Various topical skin care regimens have been 
advocated including skin grafting and topical antibiotics. Patients 
with extensive skin involvement are usually recommended to 
be treated at burn centers. In our case, all children were treated 
in the PICU with reverse isolation. Prendiville et al. [19] also 
reported successful treatment of 7 children with TEN in a 
pediatric hospital without any mortality. Topical antibiotic 
creams were not applied routinely in our study. They were used 
only at specific sites which looked infected. Daily skin care was 
provided by cleaning of wound and irrigation of unaffected skin 
with normal saline and whole body covered with autoclaved 
liquid paraffin impregnated gauze. This prevented adhesion of 
the skin to the dressing and paraffin in addition to preventing 
drying, and decreasing itching probably acted as a barrier for 
entry of organisms too. Our mortality of 7.6% is comparable to 
the 7% mortality rate reported by Spies et al. in their study on 
treatment of TEN with human allograft skin. Our study proves 
that very good treatment outcome can be achieved in patients 
with potentially life-threatening TEN even in resource-limited 
setting by appropriate skin care and health education of primary 
caretakers of the child.
As with most other studies on TEN small sample size is the 
limitation of our study. Being a rare, but severe life-threatening 
disease, more multicentric studies are needed to elucidate the 
clinical profile and identify the optimal treatment for TEN in 
children.
CONCLUSION
NSAID’s were found to be the most common cause of TEN 
in children. Skin involvement more than 80%, multi-organ 
dysfunction, hyperglycemia and need for invasive ventilation 
were found to be associated with increased risk of developing 
culture positive sepsis in our study. IVIG with parenteral steroids 
and skin care with normal saline washes and sterile liquid paraffin 
impregnated gauze was found to be an effective and safe treatment 
options for children with TEN.
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